Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the first quarter ended March 31, 2018. “We continue to advance our lead product candidate, Diazoxide Choline Controlled-Release (DCCR), in the clinic for Prader-Willi Syndrome (PWS),” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We achieved a significant milestone recently with the initiation of our Phase III clinical trial. Based on the data generated to date, we believe that DCCR has the potential to be an effective treatment option, and look forward to conducting this trial, which we expect will take approximately 9-12 months to complete.” Recent Corporate Highlights Initiated Phase III clinical trial of DCCR in PWS° Phase III trial is a randomized, double-blin
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- How Hard Is It To Be A Biotech Venture Capitalist? [Forbes]Forbes
- We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
SLNO
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEF
- 4/22/24 - Form 8-K
- SLNO's page on the SEC website